CLINICAL TRIALS PROFILE FOR CLARINEX-D 12 HOUR
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Clarinex-d 12 Hour
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00636870 ↗ | Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine | Completed | Sanofi | Phase 4 | 2003-02-01 | To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers. |
| NCT00637585 ↗ | Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine | Completed | Sanofi | Phase 4 | 2002-12-01 | To examine the relative potency, onset of action and duration of action of fexofenadine HCl 180 mg (ALLEGRA) and desloratadine 5 mg (CLARINEX) as compared to placebo on skin wheals and flares induced by histamine. |
| NCT00757562 ↗ | Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2002-11-01 | This study was conducted to evaluate the safety and tolerance of desloratadine after 5 weeks of repetitive dosing in children ages 2 to 12 years old with allergic hypersensitivity or chronic hives. All of the subjects enrolled in this trial were previously identified in an earlier trial to be poor metabolizers of desloratadine. |
| NCT00783133 ↗ | Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2002-11-01 | This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more. |
| NCT00794248 ↗ | Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2002-11-01 | This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more. |
| NCT00794495 ↗ | Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2002-12-01 | This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Clarinex-d 12 Hour
Condition Name
Clinical Trial Locations for Clarinex-d 12 Hour
Trials by Country
Clinical Trial Progress for Clarinex-d 12 Hour
Clinical Trial Phase
Clinical Trial Sponsors for Clarinex-d 12 Hour
Sponsor Name
